Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2023-05-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/9/3/00695-2022.full |
| _version_ | 1797689344390070272 |
|---|---|
| author | James D. Chalmers Mark L. Metersky Joseph Feliciano Carlos Fernandez Ariel Teper Andrea Maes Mariam Hassan Anjan Chatterjee |
| author_facet | James D. Chalmers Mark L. Metersky Joseph Feliciano Carlos Fernandez Ariel Teper Andrea Maes Mariam Hassan Anjan Chatterjee |
| author_sort | James D. Chalmers |
| collection | DOAJ |
| first_indexed | 2024-03-12T01:44:23Z |
| format | Article |
| id | doaj.art-61c3973e0866421282f4aaf04fe95e67 |
| institution | Directory Open Access Journal |
| issn | 2312-0541 |
| language | English |
| last_indexed | 2024-03-12T01:44:23Z |
| publishDate | 2023-05-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | ERJ Open Research |
| spelling | doaj.art-61c3973e0866421282f4aaf04fe95e672023-09-09T13:53:53ZengEuropean Respiratory SocietyERJ Open Research2312-05412023-05-019310.1183/23120541.00695-202200695-2022Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasisJames D. Chalmers0Mark L. Metersky1Joseph Feliciano2Carlos Fernandez3Ariel Teper4Andrea Maes5Mariam Hassan6Anjan Chatterjee7 Ninewells Hospital and Medical School, University of Dundee, Dundee, UK University of Connecticut School of Medicine, Farmington, CT, USA Insmed Incorporated, Bridgewater, NJ, USA Insmed Incorporated, Bridgewater, NJ, USA Insmed Incorporated, Bridgewater, NJ, USA Insmed Incorporated, Bridgewater, NJ, USA Insmed Incorporated, Bridgewater, NJ, USA Insmed Incorporated, Bridgewater, NJ, USA http://openres.ersjournals.com/content/9/3/00695-2022.full |
| spellingShingle | James D. Chalmers Mark L. Metersky Joseph Feliciano Carlos Fernandez Ariel Teper Andrea Maes Mariam Hassan Anjan Chatterjee Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis ERJ Open Research |
| title | Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis |
| title_full | Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis |
| title_fullStr | Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis |
| title_full_unstemmed | Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis |
| title_short | Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis |
| title_sort | benefit risk assessment of brensocatib for treatment of non cystic fibrosis bronchiectasis |
| url | http://openres.ersjournals.com/content/9/3/00695-2022.full |
| work_keys_str_mv | AT jamesdchalmers benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis AT marklmetersky benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis AT josephfeliciano benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis AT carlosfernandez benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis AT arielteper benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis AT andreamaes benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis AT mariamhassan benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis AT anjanchatterjee benefitriskassessmentofbrensocatibfortreatmentofnoncysticfibrosisbronchiectasis |